Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERI: Primovist NSF Risk in Renal Impairment
NCT00908596Phase 4Completed
- Sponsor
- Bayer
- Start
- May 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 4 trial of gadoxetate disodium in liver disease, sponsored by Bayer. Started May 2009; status: completed.
02
Drugs
gadoxetate disodium
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT00908596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908596.